-
DZNep: Evidence, Mechanisms, and Research Context
2026-10-05
3-Deazaneplanocin (DZNep) is a mechanistic epigenetic research compound best understood as an indirect disruptor of EZH2-associated repression through S-adenosylhomocysteine hydrolase inhibition. This overview compares evidence from cancer models, highlights applications in AML and hepatocellular carcinoma research, and explains why context, assay choice, and source quality limit translational interpretation.
-
Tunicamycin and the N-Glycosylation–Treg Axis
2026-10-05
Tunicamycin offers a mechanistic lens for studying how disrupted N-glycosylation reshapes ER homeostasis, inflammatory signaling, and tumor immunity. Building on a 2026 Cellular Oncology study of the STT3A–FCN3–Wnt/β-catenin axis in hepatocellular carcinoma, this article outlines the translational value and limitations of connecting broad glycosylation stress with glycoprotein-specific immune regulation.
-
Tripod-Like LuT Lipids for Lung-Targeted LNPs
2026-10-04
A Nature Biomedical Engineering study evaluated 444 quaternary amino lipids and identified a tripod-like structural motif associated with selective lung delivery. Lead 1A7B13 lipid nanoparticles improved mRNA and CRISPR–Cas9 delivery in mice, providing a useful structure–activity framework while remaining preclinical and formulation-dependent.
-
NVP-BGJ398 Phosphate: FGFR Workflow Guide
2026-10-02
NVP-BGJ398 phosphate is a potent FGFR1–3 research inhibitor for connecting genotype, receptor phosphorylation, and phenotype. This practical guide covers cancer-cell screening, chondrocyte assays, formulation, controls, and troubleshooting across translational workflows.
-
Dextran sulfate sodium salt: DSS Colitis Workflow
2026-10-01
Build a controlled intestinal inflammation model with Dextran sulfate sodium salt and connect epithelial injury to mucosal repair biology. This workflow emphasizes preparation, sampling, troubleshooting, and GPR35-KLF5-focused assay design for ulcerative colitis research.
-
SAR131675: VEGFR-3 Inhibitor Workflows
2026-10-01
Build cleaner lymphangiogenesis, angiogenesis, and VEGFC–macrophage assays with SAR131675, a selective ATP-competitive tool compound. This workflow-focused guide connects target engagement to functional readouts while emphasizing formulation, selectivity, and preclinical limitations.
-
OCT2 and MATE1 Inhibition by 5-HT3 Antiemetics
2026-09-30
George and colleagues compared five 5-HT3 antagonists in complementary human transporter models and identified substantial differences in inhibition of OCT2- and MATE1-mediated cation transport. The findings clarify how antiemetic exposure could alter renal secretion of coadministered organic cations, while also defining important limits on extrapolating in vitro potency to clinical drug–drug interactions.
-
Low-Dose Orlistat Enhances Oxaliplatin in CRC
2026-09-30
The reference study reports that low-dose orlistat sensitized colorectal cancer models to Oxaliplatin, producing synergistic cytotoxicity and apoptosis in cultured cells and patient-derived xenografts. Its combination of in silico synergy analysis, PDX validation, and an 85-gene apoptosis array provides a useful preclinical framework for evaluating metabolic chemosensitization.
-
Regulated Platelet Extravasation in Tumors
2026-09-29
The reference study identifies platelet transendothelial migration into tumors as a regulated process controlled by CXCL12/CXCR4, FAK, PECAM-1, and distinct granule-secretion pathways. Its findings separate platelet trafficking from platelet effector activity, offering a mechanistic framework for interpreting how vascular entry influences tumor growth.
-
NAT1–ENO1–Lactate Axis in Colorectal Cancer
2026-09-29
A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator in colorectal cancer, linking ENO1 acetylation and lactate production to TRAF6-dependent PD-L1 stabilization. Its public-dataset, multi-omics, cellular, patient, and mouse-model evidence provides a mechanistic framework for studying how tumor glycolysis influences checkpoint therapy.
-
HA mRNA Vaccine Protects Dairy Cows Against H5N1
2026-09-28
A hemagglutinin-based mRNA–lipid nanoparticle vaccine protected lactating dairy cows against H5N1 challenge and was reported to be well tolerated without adverse effects on health or milk production. The findings support further evaluation of mRNA vaccination in cattle, while leaving important questions about study design, durability, and field effectiveness for future research.
-
Ruxolitinib (INCB018424): Assay Design Guide
2026-09-27
A practical guide to using Ruxolitinib (INCB018424), SKU A3012, in cell viability, proliferation, and immune-profiling workflows. Review target potency, solvent handling, assay interpretation, and the limits of translating combination-therapy findings across models.
-
Dasatinib Monohydrate in Gastric Assembloids
2026-09-26
Use Dasatinib Monohydrate to test kinase dependence and stromal modulation in patient-derived gastric cancer assembloids—not to assume a gastric-cancer indication. A paired organoid-versus-assembloid workflow can reveal whether tumor–stroma context changes response, while careful vehicle controls and cell-specific readouts help interpret the result.
-
hiPSC-Derived Intestinal Organoids for PK Studies
2026-09-26
Saito and colleagues report a direct three-dimensional cluster-culture approach for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. When transferred to a two-dimensional culture, the organoids produce intestinal epithelial cells with metabolizing-enzyme and transporter activity, supporting their evaluation as a human-relevant platform for pharmacokinetic studies.
-
Perphenazine: Dopamine D2 Antagonist Research
2026-09-25
Perphenazine is a dopamine D2 receptor antagonist with a documented receptor-binding profile and research findings spanning neuronal cell stress, opioid tolerance suppression, and macrophage antibacterial activity. The evidence supports several experimental applications, but it does not make research findings interchangeable with clinical conclusions.